Alkermes director sells 2,000 shares in plan

Alkermes plc director Christopher I. Wright reported an open-market sale of 2,000 Ordinary Shares at a price of $45.10 per share.

Filing Impact

(Neutral)

Filing Sentiment

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Alkermes plc director Christopher I. Wright reported an open-market sale of 2,000 Ordinary Shares at a price of $45.10 per share. After this transaction, he directly holds 25,680 Ordinary Shares.

The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted by Wright on March 11, 2026, indicating the trade was scheduled in advance rather than timed discretionarily.

Insider Trade Summary 10b5-1

Net Seller: 2,000 shares

Net Sell 1 txn

Insider Wright Christopher I

Role Director

Sold 2,000 shs ($90K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	2,000	$45.10	$90K

Holdings After Transaction: Ordinary Shares — 25,680 shares (Direct)

Footnotes (1)

F1. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/11/2026.

Key Figures

Shares sold: 2,000 shares Sale price: $45.10 per share Shares held after sale: 25,680 shares +1 more

4 metrics

Shares sold 2,000 shares Open-market sale of Alkermes Ordinary Shares

Sale price $45.10 per share Price for 2,000 Ordinary Shares sold

Shares held after sale 25,680 shares Direct ownership following the transaction

Net shares sold 2,000 shares Net-sell direction from transaction summary

Key Terms

Rule 10b5-1 trading plan, open-market sale, Ordinary Shares

3 terms

Rule 10b5-1 trading plan financial

"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted..."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Ordinary Shares financial

"security_title: Ordinary Shares"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Alkermes (ALKS) disclose for Christopher Wright?

Alkermes reported that director Christopher I. Wright sold 2,000 Ordinary Shares in an open-market transaction at $45.10 per share. Following the sale, he directly owns 25,680 Ordinary Shares of Alkermes, as reflected in the Form 4 filing.

At what price were the Alkermes (ALKS) shares sold in this Form 4?

The reported sale was executed at $45.10 per Alkermes Ordinary Share. This price applies to the 2,000 shares sold in the open-market transaction, as disclosed in the Form 4 insider trading report for director Christopher I. Wright.

How many Alkermes (ALKS) shares does Christopher Wright hold after the sale?

After selling 2,000 Alkermes Ordinary Shares, Christopher I. Wright directly holds 25,680 shares. This post-transaction ownership figure is disclosed in the Form 4 and reflects his remaining direct equity position in Alkermes plc.

Was the Alkermes (ALKS) insider sale made under a Rule 10b5-1 plan?

Yes. The Form 4 footnote states the 2,000-share sale was effected under a Rule 10b5-1 trading plan adopted by Christopher I. Wright on March 11, 2026. Such plans pre-schedule trades, reducing the role of discretionary timing.

What type of security did Christopher Wright trade in Alkermes (ALKS)?

Christopher I. Wright traded Alkermes Ordinary Shares in this Form 4 transaction. The filing identifies the security as “Ordinary Shares” and classifies the event as a non-derivative, open-market sale of 2,000 shares at $45.10 each.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/12/2026 - 08:04 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wright Christopher I

(Last)

(First)

(Middle)

CONNAUGHT HOUSE

1 BURLINGTON ROAD

(Street)

DUBLIN

4 Ireland

(City)

(State)

(Zip)

IRELAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
Alkermes plc. [ ALKS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Ordinary Shares	06/12/2026		S⁽¹⁾		2,000	D	$45.1	25,680	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/11/2026.

	/s/ Shantale Greenson, attorney-in-fact for Christopher I. Wright	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR